Editas Medicine Inc (EDIT) Price

Editas Revenue Climbs On Bristol Myers Milestone

Editas Medicine reported a narrower-than-expected Q3 2025 loss and a significant revenue increase, driven by a collaboration milestone payment from Bristol Myers Squibb. The results provide near-term validation, but the stock faces uncertainty amid a broader downward trend in analyst estimates.